Hikma Pharmaceuticals Plc 5.2% Potential Decrease Indicated by JP Morgan Cazenove

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Hikma Pharmaceuticals Plc using EPIC/TICKER code (LON:HIK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘NEUTRAL’ today by analysts at JP Morgan Cazenove. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. JP Morgan Cazenove have set a target price of 1800 GBX on its stock. This would indicate that the analyst believes there is a downside of -5.2% from the opening price of 1898 GBX. Over the last 30 and 90 trading days the company share price has decreased 102 points and decreased 132 points respectively. The 52 week high share price is 2212 GBX while the 52 week low for the stock is 1491.5 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 2,020.62 GBX and a 200 day moving average of 1,865.70. There are currently 242,319,010 shares in issue with the average daily volume traded being 436,454. Market capitalisation for LON:HIK is £4,602,849,594 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities.

      Search

      Search